Frideres et al. Target trial emulation in RA-ILD. Primar outcome death or respiratory hospitialization. Abatacept (aHR 0.90), tocizilumab (aHR 0.93), tofacitinib (aHR 0.69) vs rituximab. @RheumNow #ACR24 Abstr#1713 https://t.co/fbE8xAnzQ2 https://t.co/uwzH8oAyAT

• Comparisons of Non-TNFi Biologic and Targeted Synthetic DMARDs in Rheumatoid Ar…
• https://x.com/RichardPAConway/status/1858242203380003024/photo/1

A picture is worth a thousand words—and so are the four abstracts behind it! At #ACR24, I highlight the benefits and risks of apremilast in #PsA. @RheumNow https://t.co/ospR0qEIsd

• Apremilast Benefits and Risks in PsA | RheumNow

Chevet et al. What happens when you withdraw tocilizumab after 6 months in PMR? Follow up of SEMAPHORE study. 80.8% relapsed! Median time to relapse 15 weeks. @RheumNow #ACR24 Abstr#1698 https://t.co/9pJ88C05V2

• https://x.com/RichardPAConway/status/1858223581034856800/photo/1

Is #IL1 inhibition for 4 months a winner in #GCA —NOPE Anakinra daily 100mg sc 4/12 Underpowered but equal relapses and d/c #steroids not different #relapses esp after d/c #anakinra N=30 d/c due to #COVIDpandemic #1699 #ACR24 @RheumNow @ACRheum https://t.co/1TgloS5x8O

• https://x.com/Janetbirdope/status/1858224593452113923/photo/1

#HRT is not much of a risk of Breast cancer Compared to A drink a day of #ETOH #ACR24 @RheumNow @ACRheum https://t.co/LFgqbFocpb

• https://twitter.com/rheum2improve/status/1858215861510652040

de Boysson et al. RCT anakinra in GCA. 30 patients. Week 52 relapse 53% in anakinra vs 46% in placebo. @RheumNow #ACR24 Abstr#1699 https://t.co/sqDWUlkXAX

• https://x.com/RichardPAConway/status/1858227355447378085/photo/1

Sarilumab is better than #MTX in #PMR Reminder #RCT of #MTX in #PMR was a NEGATIVE #trial #1697 60 % #sarilumab in #RWE could d/c #Prednisone after failure of initial #pred #Rx >1yr pred prior vs 40% MTX Comparative effectiveness sari v MTX #1700 #ACR24 @ACRheum @RheumNow https://t.co/4YXIBz0OK7

• https://x.com/Janetbirdope/status/1858228695531393051/photo/1
• https://x.com/Janetbirdope/status/1858228695531393051/photo/1

A retrospective analysis by Dr. ERayens et al showed that RA pts >/=50y given 2 RZV doses were less likely to develop HZ vs. unvaxxed grp Incidence of PHN was also lower in the vaccinated group (0.2py vs.1.9py) RZV is effective in preventing HZ & PhN @Rheumnow #ACR25 abs0977 https://t.co/JhYBYnLmhl

• https://x.com/RHEUMarampa/status/1858219577865331006/photo/1